AndroGel Cost in South Carolina 2026: Cash Pay, Insurance, and Compounded Alternatives

What Does AndroGel Actually Cost in South Carolina Right Now?

The manufacturer list price for AndroGel is approximately $510 per month for a standard 30-day supply in 2026, and South Carolina retail pharmacies price it in the same range without insurance or a discount program. That figure applies to both the 1% and 1.62% formulations. For men paying entirely out of pocket, the number rarely drops below $480 at any major chain in the state.

AbbVie, the manufacturer, set the wholesale acquisition cost (WAC) at a level that puts AndroGel among the higher-priced topical testosterone products on the U.S. market. The FDA approved testosterone gel under NDA 021449, and the current prescribing information is available through the FDA's drug database. That label governs dosing, contraindications, and the black-box warning about secondary exposure in women and children, which remains clinically relevant regardless of which formulation a patient uses.

Retail price fluctuates slightly across ZIP codes in South Carolina. A pharmacy in Columbia may quote $505; one in Greenville or Charleston may quote $512. The variance rarely exceeds $30 in either direction. GoodRx and similar coupon aggregators can pull the price to approximately $460 to $490 at select pharmacies, though coupon pricing cannot be combined with insurance.

South Carolina has no state-level drug price transparency program that applies specifically to testosterone products, so there is no public database tracking local price trends the way some other states track insulin. Patients who want the lowest cash price should call at least three pharmacies directly, because posted GoodRx prices do not always match what the pharmacy's dispensing system will honor at the counter.

Does South Carolina Medicaid Cover AndroGel?

South Carolina Medicaid does not cover AndroGel for male hypogonadism. This is consistent across all Medicaid managed care organizations (MCOs) operating in the state as of 2026. The SC Department of Health and Human Services Preferred Drug List places branded testosterone gel in a non-covered tier for the hypogonadism indication.

Some MCOs will cover generic testosterone gel (approved under ANDA filings) under specific prior authorization criteria, but coverage is not guaranteed and varies by plan. Patients enrolled in South Carolina Healthy Connections Medicaid should request a coverage determination letter before assuming any testosterone product will be paid for.

The Centers for Medicare and Medicaid Services (CMS) outlines how states may restrict coverage of Schedule III controlled substances, and South Carolina exercises that latitude broadly for testosterone products. Medicare Part D plans administered in South Carolina treat AndroGel differently from Medicaid. Most Part D formularies place it on Tier 3 or Tier 4, meaning a 30-day copay typically ranges from $90 to $200 after the deductible, depending on the specific plan.

Men over 65 who qualify for Medicare should check their Part D Summary of Benefits before assuming it is not covered. The T-Trials, published in the New England Journal of Medicine, enrolled 788 men aged 65 or older with low testosterone and demonstrated statistically significant improvements in sexual function (P<0.001 for the sexual activity domain) and bone density at 12 months. That evidence base is one reason some Medicare Part D plans do include the drug, particularly when a physician documents symptomatic hypogonadism with a confirmed serum total testosterone below 275 ng/dL on two morning measurements.

The Endocrine Society's 2018 clinical practice guideline states: "We recommend testosterone therapy for men with symptomatic androgen deficiency to improve sexual function, muscle mass and strength, and bone mineral density." That language supports prior authorization appeals when insurers deny coverage.

Which Private Insurance Plans in South Carolina Cover AndroGel?

Coverage depends heavily on the employer plan, the insurer's specific formulary, and whether a prior authorization is approved. The major commercial insurers operating in South Carolina in 2026 include BlueCross BlueShield of South Carolina, Aetna, Cigna, and UnitedHealthcare. Each maintains a distinct formulary.

BlueCross BlueShield of South Carolina's standard commercial formulary places AndroGel on Tier 3 with a prior authorization requirement. Approved claims typically result in a member copay of $50 to $150 per 30-day supply, depending on the plan design. Aetna's South Carolina plans generally place branded testosterone gel on Tier 4 with step therapy: a prescriber must document that the patient either failed or is contraindicated for a lower-cost generic testosterone product first.

Step therapy is the most common barrier. A prescriber can typically satisfy it by documenting that the patient experienced skin irritation, absorption issues, or another clinically relevant problem with a generic product. The appeal process matters here. CMS guidance on step therapy exceptions notes that exceptions must be granted when step therapy is "not clinically appropriate," and South Carolina follows federal protections for Medicare Advantage step therapy exceptions enacted in 2019.

Getting prior authorization approved often comes down to documentation quality. A prescriber who submits two morning serum testosterone values below 275 ng/dL, a list of symptoms consistent with hypogonadism, and a note ruling out secondary causes has a much stronger case than one who submits a single lab value.

How Does the AbbVie Savings Card Work in South Carolina?

AbbVie offers a savings card program that can reduce the out-of-pocket cost of AndroGel to as low as $0 per month for commercially insured patients who meet eligibility criteria. The program is called myAbbVie Assist for patients who are uninsured or underinsured, and the AndroGel Savings Card targets those with commercial insurance.

Eligibility restrictions apply. Patients enrolled in any federal or state government health program, including South Carolina Medicaid, Medicare, TRICARE, or the Veterans Administration, are not eligible for the commercial savings card. This exclusion is standard across most manufacturer assistance programs and is not unique to AbbVie.

For an eligible commercially insured patient in South Carolina, the savings card functions as a secondary payer at the pharmacy. The commercial insurance adjudicates the claim first, and the savings card covers the remaining patient cost share, subject to an annual maximum benefit cap. AbbVie has periodically adjusted that cap; patients should verify the current cap directly at the AbbVie website or by calling the program line, because the cap can change between benefit years.

Uninsured South Carolina residents who do not qualify for Medicaid may apply for the myAbbVie Assist patient assistance program. Income thresholds and documentation requirements apply. Processing a full assistance program application typically takes two to four weeks, which means patients should not wait until they run out of medication to apply.

Is Compounded Testosterone Gel Legal in South Carolina?

Yes. Licensed 503A compounding pharmacies in South Carolina can legally prepare and dispense compounded testosterone gel when a physician or other licensed prescriber writes a patient-specific prescription. This is not a legal gray area. The FDA's framework for 503A compounding pharmacies permits this explicitly, provided the pharmacy is state-licensed, the compound is not essentially a copy of a commercially available product without clinical justification, and the prescription is for an identified individual patient.

Compounded testosterone gel in South Carolina averages approximately $120 per month, compared with $510 for branded AndroGel. That is a cost difference of roughly $390 per month, or $4,680 per year. For men paying cash, that figure is significant.

The clinical question is whether compounded testosterone gel provides the same therapeutic effect as the branded product. The FDA has not approved any compounded drug, which means compounded testosterone gel has not undergone the same bioequivalence testing that generic manufacturers must complete. Absorption rates can differ depending on the vehicle (carrier gel base), concentration, and compounding technique used by the pharmacy. A prescribing clinician should document the rationale for choosing a compounded product and monitor serum testosterone levels after initiation to confirm the patient achieves a therapeutic range, generally 400 to 700 ng/dL for most adult men, though target ranges may differ based on individual clinical context.

South Carolina's Board of Pharmacy licenses and inspects 503A pharmacies. Patients should confirm that their compounding pharmacy holds a current South Carolina license before filling a prescription. Pharmacies operating under FDA's 503B outsourcing facility designation cannot dispense directly to individual patients under a patient-specific prescription in the same way 503A pharmacies can; 503B facilities supply healthcare facilities in bulk.

The Endocrine Society's position on compounded bioidentical hormones notes that compounded preparations lack the standardization and safety data of FDA-approved products, and advises that clinicians document the clinical rationale when prescribing them. That documentation also protects the prescriber if a payer or regulator later questions the choice.

Can You Get an AndroGel Prescription via Telehealth in South Carolina?

Telehealth prescribing of testosterone gel is legal in South Carolina. A licensed physician, nurse practitioner, or physician assistant who holds a valid South Carolina license can prescribe AndroGel or compounded testosterone gel through a telehealth encounter, provided the encounter meets standard-of-care requirements.

Those requirements include a medical history review, symptom assessment, and review of laboratory results confirming low testosterone. South Carolina follows the Ryan Haight Online Pharmacy Consumer Protection Act for controlled substance prescribing, which classifies testosterone as a Schedule III controlled substance. That classification means a valid prescriber-patient relationship must exist before a telehealth provider can issue the prescription, and an in-person evaluation may be required for some prescribers' practice policies.

The practical implication: a telehealth platform cannot legally prescribe testosterone based on a symptom questionnaire alone. The prescriber must review laboratory results. Two morning fasting serum total testosterone measurements, drawn before 10 a.m., are the standard. If both fall below 275 ng/dL (per Endocrine Society guidelines) and the patient has clinical symptoms, the prescriber has the evidentiary basis to proceed.

Several telehealth platforms operating in South Carolina send lab orders to LabCorp or Quest Diagnostics locations statewide, which simplifies the process for patients who do not have a local endocrinologist. Once labs are reviewed and a prescription is issued, the telehealth provider can route the prescription to a local retail pharmacy for AndroGel or to a licensed 503A compounding pharmacy for a compounded formulation. Total time from first appointment to medication in hand is typically five to ten business days.

Clinical Evidence Supporting Testosterone Gel Therapy

The evidence base for testosterone gel rests on several large trials. The T-Trials, a coordinated set of seven placebo-controlled trials conducted at 12 U.S. sites, remains the most cited. The main results, published in the New England Journal of Medicine in 2016 (N=788 men, mean age 72), showed that testosterone treatment increased serum testosterone to mid-normal range in the treatment group and produced statistically significant improvements in sexual desire, erectile function, and walking distance at 12 months compared with placebo.

Bone density results from the T-Trials' bone sub-study showed that testosterone increased volumetric bone density in the spine by 7.5% and trabecular bone score improved significantly (P<0.001), findings published separately in the New England Journal of Medicine. These results inform why prescribers consider testosterone therapy not only for sexual symptoms but also for men with osteopenia and documented hypogonadism.

The Endocrine Society 2018 guideline on male hypogonadism recommends testosterone therapy for men with classic hypogonadism (primary or secondary), symptoms of androgen deficiency, and consistently low serum testosterone. The guideline specifies that treatment should not be offered to men who want fertility in the near term, men with hematocrit above 50%, untreated severe obstructive sleep apnea, or uncontrolled heart failure.

The guideline further recommends monitoring hematocrit at three to six months after initiation and annually thereafter, because testosterone therapy can stimulate erythropoiesis. A hematocrit above 54% is a standard threshold at which prescribers reduce dose or pause therapy.

How to Get the Lowest Price on Testosterone Gel in South Carolina

The lowest-cost path for an uninsured or underinsured South Carolina resident in 2026 is compounded testosterone gel from a licensed 503A pharmacy, at approximately $120 per month. That requires a valid prescription from a licensed South Carolina prescriber, which a telehealth consultation can provide if in-person access is limited.

For commercially insured patients, the AbbVie savings card combined with a successful prior authorization can bring the cost to near zero, at least for the period covered by the annual card benefit. Patients should apply for the savings card at the same time the prior authorization is submitted, not after the PA is approved, to avoid a gap in coverage.

GoodRx codes applied at the pharmacy counter represent a third option for patients whose insurance does not cover testosterone gel and who prefer a regulated branded or generic product over a compounded one. GoodRx pricing for generic testosterone gel 1.62% in South Carolina ranges from approximately $85 to $130 per month depending on pharmacy and pack size, which is competitive with compounded gel pricing and has the advantage of FDA-reviewed bioequivalence data.

Patients who qualify for VA benefits should contact their VA primary care provider first. The Veterans Affairs formulary covers testosterone gel for eligible veterans with documented hypogonadism at no or very low cost, and the VA's evidence-based prescribing protocols align with Endocrine Society guidelines.

The following decision pathway summarizes the cost-minimization approach for South Carolina patients:

1. Confirm diagnosis with two morning serum testosterone levels below 275 ng/dL plus symptoms.
2. Check commercial insurance formulary for testosterone gel coverage and prior authorization requirements.
3. If insured commercially: submit PA documentation, apply for AbbVie savings card, target $0 to $50/month.
4. If on Medicaid: request coverage determination, expect denial for branded product, evaluate generic testosterone gel under PA or compounded 503A gel at ~$120/month.
5. If uninsured: compare GoodRx generic testosterone gel (~$85 to $130/month) against a 503A compounded prescription (~$120/month), factoring in whether bioequivalence data matters for the individual clinical situation.
6. Monitor serum testosterone at 3 months after initiation to confirm therapeutic levels (target 400 to 700 ng/dL for most men).

Safety Considerations South Carolina Prescribers and Patients Should Know

AndroGel carries a black-box warning for secondary exposure. Children and women who come into contact with testosterone gel on the skin of a male user can absorb the hormone, leading to premature puberty in children and virilization in women. The FDA's prescribing label mandates patient counseling on application sites, hand washing after application, and covering the application area with clothing before contact with others.

The FDA Drug Safety Communication on testosterone and cardiovascular risk advises that testosterone products are approved only for men with low testosterone caused by a medical condition such as hypogonadism, not for age-related decline alone. Prescribers in South Carolina should document the specific diagnosis code (ICD-10 E29.1 for primary testicular failure, or E23.0 for secondary hypogonadism) to support insurance coverage and to maintain accurate medical records.

Cardiovascular risk remains an active area of research. The TRAVERSE trial, published in the New England Journal of Medicine in 2023 (N=5,246 middle-aged and older men with hypogonadism and pre-existing or high cardiovascular risk), found that testosterone replacement was non-inferior to placebo for the primary composite cardiovascular endpoint (MACE) over a median follow-up of 22 months. The trial did find higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group, findings that inform risk-benefit discussions with patients who have pre-existing cardiovascular disease.

A serum hematocrit at baseline, three months, and annually is the minimum monitoring standard. Serum testosterone should be checked at three months after starting gel therapy, with a target trough of 400 to 700 ng/dL. If levels fall outside that range, the prescriber adjusts dose before the next lab check.